Lindus Health Raises £45M Series B to Revolutionise Clinical Trials

Transforming the Clinical Trial Landscape

Lindus Health, known as “the anti-CRO”, has announced the close of a £45 million Series B funding round led by Balderton Capital, with participation from Visionaries Club and existing investors Creandum, Firstminute Capital, and Seedcamp. This funding will accelerate the development of Lindus Health’s proprietary AI-powered eClinical platform, Citrus™, and expand its operations to redefine how clinical trials are conducted.

The Need for Disruption in Clinical Trials

1. Challenges with Traditional CROs

• 85% of clinical trials are delayed, causing inefficiencies that hinder drug development.

• The cost of developing a single drug has skyrocketed, increasing by nearly £250 million from 2021 to 2022 alone.

• The stagnant CRO industry lacks adoption of modern technology, driving higher research costs and delaying patient access to new treatments.

2. Lindus Health’s Tech-First Approach

Lindus Health is disrupting the £90 billion CRO industry by:

• Leveraging big data and AI to optimise study design.

• Automating central monitoring of study data for faster, more accurate results.

• Using Citrus™ to provide instant biostatistics, central patient recruitment, and new trial designs.

Lindus Health’s Impact

Efficiency and Cost-Effectiveness

• Clinical trials are up to three times faster than traditional models.

• Improved quality of trial data reduces costs and enables life sciences companies to iterate faster.

• Lower research and healthcare costs lead to affordable treatments for patients.

Transforming Drug Development

• By replacing outdated “waterfall” models with agile research methodologies, Lindus Health allows companies to:

  • Innovate rapidly.

  • Explore new therapeutic approaches.

  • Translate breakthroughs into patient-ready solutions faster.

Statements from Leadership and Investors

Meri Beckwith, Co-Founder, Lindus Health

"The antiquated CRO model is failing the industry and patients. Lindus is completely reinventing how clinical trials operate, breaking the cycle of inefficiencies, and enabling life science companies to innovate faster."

Michael Young, Co-Founder, Lindus Health

"The last two decades have brought huge scientific breakthroughs, but clinical trial bottlenecks prevent these innovations from reaching the public. We’re introducing a paradigm shift in trials, powered by technology, to change the way drug development works."

Suranga Chandratillake, Partner, Balderton Capital

"Lindus Health’s vision for clinical trials and their unwavering commitment to patient outcomes sets them apart. This pioneering mission to build the anti-CRO will help translate breakthroughs in life sciences and AI into therapeutics that improve millions of lives."

Funding Allocation and Future Plans

Advancing Technology

• Further development of Citrus™ to enhance trial design, monitoring, and data analysis.

• Expanding AI capabilities to improve trial efficiency and outcomes.

Scaling Operations

• Hiring across clinical operations, product development, and engineering.

• Broadening Lindus Health’s presence to serve more life science companies globally.

Improving Patient Access

• Faster trial processes to reduce time-to-market for groundbreaking treatments.

• Lower costs to make healthcare more accessible and equitable.

The Road Ahead

This £45 million funding round marks a pivotal moment in Lindus Health’s journey to revolutionise clinical research. By leveraging cutting-edge technology and breaking free from outdated industry norms, Lindus Health is setting the stage for faster, more reliable trials and groundbreaking treatments that will improve healthcare outcomes for millions of patients worldwide.